Drug profile · INN
zoledronic acid
ACLASTA
zoledronic acid (ACLASTA) is a farnesyl diphosphate synthase inhibitor. Associated with Apotex Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — zoledronic acid
- US status
- approved
- Class
- Musculo-skeletal system (M05)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
zoledronic acid (ACLASTA) is a farnesyl diphosphate synthase inhibitor. Associated with Apotex Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Farnesyl diphosphate synthase inhibitor
Primary target: Farnesyl pyrophosphate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zoledronic acid?
zoledronic acid (ACLASTA) is a farnesyl diphosphate synthase inhibitor. Associated with Apotex Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for zoledronic acid?
ACLASTA is a marketed brand name for zoledronic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zoledronic acid?
zoledronic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.